[MOL] Arp,asos now available in us for advanced breast cancer.... [00995] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Arp,asos now available in us for advanced breast cancer....

Aromasin Now Available In US For Advanced Breast Cancer

PEAPACK, N.J. -- January 24, 2000 -- Pharmacia & Upjohn announced the availability of Aromasin(R) (exemestane tablets), the first oral aromatase inactivator for the treatment of postmenopausal women with advanced breast cancer whose tumors stop responding to tamoxifen therapy. The introduction of Aromasin closely follows another breast cancer milestone for Pharmacia & Upjohn. On October 11, the company launched Ellence(TM) (epirubicin hydrochloride injection), as a component of adjuvant therapy for the treatment of early node-positive breast cancer.

"Aromasin is the second new breast cancer treatment we've brought to patients in just four months, and with this launch, Pharmacia & Upjohn is solidifying its position as a global leader in cancer care," said Carrie Smith Cox, executive vice president, Global Business Management. "We are pleased to be able to offer both cytotoxic and hormonal breast cancer treatments that are not only new and effective but also options that treat early- or late-stage breast cancer."

Unlike agents currently available, Aromasin is the first oral hormonal therapy that binds irreversibly to the aromatase enzyme, an action that interferes with the supply of estrogen to the cancerous tumors that are dependent on the hormone.

The unique mechanism of action has prompted a prestigious cooperative cancer study group to begin further study of Aromasin. The European Organization for Research and Treatment of Cancer (EORTC) has recently concluded a randomized Phase II trial of Aromasin versus tamoxifen as first line hormonal therapy in postmenopausal breast cancer patients. The data from this trial has been submitted to the American Society of Clinical Oncology for consideration for their annual meeting.

Pharmacia & Upjohn gained FDA approval for Aromasin in the fourth quarter of 1999. Aromasin is currently available in Switzerland, the United Kingdom, Germany and the Nordic nations. Pharmacia & Upjohn anticipates Aromasin to be available in France, Italy, the Netherlands, Belgium, Spain, Portugal and Latin America by the middle of this year.

Like some other hormonal therapies, Aromasin should not be administered to women with premenopausal endocrine status, or coadministered with estrogen-containing agents that can interfere with its action. Adverse events associated with Aromasin are typically mild to moderate and include hot flashes, nausea and fatigue.

Warmly, lillian
We invite you to take a look at our Album.                                               
  ( Very informational, good tips, Molers pictures, art work and much more....